1-4 of 4
Myung Ju Ahn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier, Aleksandra A. Markovets, Myung Ju Ahn, Lecia V. Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, Wu-Chou Su, Dariusz M. Kowalski, Sergey Orlov, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne
Journal: Cancer Discovery
Cancer Discov (2023) 13 (1): 98–113.
https://doi.org/10.1158/2159-8290.CD-22-0586
Published: 09 January 2023
View article titled, Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <em>MET</em>-Amplified Non–Small Cell Lung Cancer: TATTON
Open the PDF for Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, <em>MET</em>-Amplified Non–Small Cell Lung Cancer: TATTON in another window
Includes: Supplementary data
Journal Articles

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Alexander Drilon, Siqing Fu, Manish R. Patel, Marwan Fakih, Ding Wang, Anthony J. Olszanski, Daniel Morgensztern, Stephen V. Liu, Byoung Chul Cho, Lyudmila Bazhenova, Cristina P. Rodriguez, Robert C. Doebele, Antoinette Wozniak, Karen L. Reckamp, Tara Seery, Petros Nikolinakos, Zheyi Hu, Jennifer W. Oliver, Denise Trone, Katherine McArthur, Rupal Patel, Pratik S. Multani, Myung-Ju Ahn
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (3): 384–395.
https://doi.org/10.1158/2159-8290.CD-18-0839
Published: 01 March 2019
View article titled, A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Open the PDF for A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105 in another window
Includes: Supplementary data
Journal Articles

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung-Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (10): 1227–1236.
https://doi.org/10.1158/2159-8290.CD-18-0484
Published: 02 October 2018
View article titled, Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Open the PDF for Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations in another window
Includes: Supplementary data
Journal Articles

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D. Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo G. De Braud
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (4): 400–409.
https://doi.org/10.1158/2159-8290.CD-16-1237
Published: 02 April 2017
View article titled, Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Open the PDF for Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) in another window
Includes: Supplementary data